Eli Lilly and Company
CompanyUnited StatesFounded 1875
Eli Lilly and Company develops 103 assets, the furthest approved (abemaciclib in Advanced or Metastatic Breast Cancer). Mostly small molecule and antibody acting on GLP1R, ESR1 and INSR; based in the United States, founded in 1875.
- 103
- Assets
- Furthest stage
- Approved
- 2
- Grants
- 1,476
- Trials
- 989
- Signals
Pipeline
103Inhibits CDK4 and CDK6 to block cell cycle progression and cancer cell proliferation.
Approved, Small molecule, CDK6, CDK4, Advanced or Metastatic Breast Cancer, early breast cancer
Approved, PDE5A, pulmonary arterial hypertension, benign prostatic hyperplasia (Phase 3)
Selective JAK1 and JAK2 inhibitor that reduces inflammatory signaling pathways.
Approved, Small molecule, JAK2, JAK1, Active Rheumatoid Arthritis, rheumatoid arthritis
100 more assets
Full company profiles: pipeline, trials, funding and people.
Subsidiaries
123 assets, 5 trials
2 assets, 3 trials
1 asset, 40 trials
1 asset, 6 trials
1 asset, 1 trial
1 asset
1 asset
16 trials
4 trials
4 trials
3 trials
1 trial
In the full profile
- Evidence behind the mechanisms12
- Trials1,992
- Deals12
- Signals20
- Integrity notices3
- Similar companies6
Papers
Toward a Healthier Future Through Obesity Prevention and Care: The JAMA Summit Report on Obesity
JAMA, Nov 17, 2026
Blood marker linked to advanced Alzheimer’s brain tangles
JAMA, Nov 17, 2026
Orforglipron linked to lower blood pressure across groups
Diabetes, obesity & metabolism, Nov 11, 2026
Arthritis & rheumatology (Hoboken, N.J.), Nov 11, 2026
Orforglipron reduced sleep apnea severity in two trials
JAMA, Nov 9, 2026
Orforglipron increased metabolic syndrome resolution in trials
AHA Scientific Sessions 2026 abstract, Nov 9, 2026
AHA Scientific Sessions 2026 abstract, Nov 9, 2026
Effects of Orforglipron on Blood Pressure: Post-Hoc Analyses from ATTAIN-1 and ATTAIN-2 Trials
AHA Scientific Sessions 2026 abstract, Nov 9, 2026
Adults with obesity reported better function on orforglipron
Obesity pillars, Nov 8, 2026
Retatrutide cut knee osteoarthritis pain in obesity without diabetes
The New England journal of medicine, Nov 8, 2026
AHA Scientific Sessions 2026 abstract, Nov 7, 2026
AHA Scientific Sessions 2026 abstract, Nov 7, 2026
AHA Scientific Sessions 2026 abstract, Nov 7, 2026
Orforglipron reduced weight in Japanese adults with obesity
The lancet. Diabetes & endocrinology, Oct 31, 2026
Diabetes, obesity & metabolism, Oct 29, 2026
Orforglipron linked to weight loss in a trial subgroup
Obesity pillars, Oct 27, 2026
Tirzepatide tied to fewer cardiovascular events than dulaglutide
ESC Congress 2026 abstract, Oct 26, 2026
Retatrutide reduced sleep apnea severity in randomized trials
The New England journal of medicine, Oct 22, 2026
European journal of preventive cardiology, Oct 15, 2026
Obesity pillars, Oct 5, 2026